Myasthenia gravis activities of daily living profile

被引：408

作者：

Wolfe, GI

Herbelin, L

Nations, SP

Foster, B

Bryan, WW

Barohn, RJ

机构：

[1] Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA

[2] Univ Texas, SW Med Ctr Acad Comp Serv, Dallas, TX 75235 USA

来源：

NEUROLOGY | 1999年 / 52卷 / 07期

关键词：

D O I：

10.1212/WNL.52.7.1487

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors have developed an MG activities of daily living (ADL) profile (MG-ADL)-a simple eight-question survey of MG symptoms. In 254 consecutive encounters with established MG patients, the authors compared scores from the MG-ADL to the quantitative MG score (QMG)-a standardized, reliable scale used in clinical trials. The mean MG-ADL score was 4.89 +/- 3.63. The mean QMG score was 10.80 +/- 5.70. Pearson's correlation coefficient was 0.583 (p < 0.001). The MG-ADL is an easy-to-administer survey of MG that correlates well with the QMG and can serve as a secondary efficacy measurement in clinical trials.

引用

页码：1487 / 1489

页数：3

共 7 条

[1] Reliability testing of the quantitative myasthenia gravis score [J].

Barohn, RJ ;

McIntire, D ;

Herbelin, L ;

Wolfe, GI ;

Nations, S ;

Bryan, WW .

MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 :769-772

[2] MYASTHENIA-GRAVIS - LONG-TERM CORRELATION OF BINDING AND BUNGAROTOXIN BLOCKING ANTIBODIES AGAINST ACETYLCHOLINE-RECEPTORS WITH CHANGES IN DISEASE SEVERITY [J].

BESINGER, UA ;

TOYKA, KV ;

HOMBERG, M ;

HEININGER, K ;

HOHLFELD, R ;

FATEHMOGHADAM, A .

NEUROLOGY, 1983, 33 (10) :1316-1321

[3] Long-term outcome and quality of life after thymectomy for myasthenia gravis [J].

Busch, C ;

Machens, A ;

Pichlmeier, U ;

Emskotter, T ;

Izbicki, JR .

ANNALS OF SURGERY, 1996, 224 (02) :225-232

[4] Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS [J].

McGuire, D ;

Garrison, L ;

Armon, C ;

Barohn, R ;

Bryan, W ;

Miller, R ;

Parry, G ;

Petajan, J ;

Ross, M ;

Alternus, P ;

Amox, D ;

Ashburn, C ;

Aulenbacher, D ;

Blasucci, L ;

Brown, E ;

Caulkins, M ;

Carozza, C ;

Dao, H ;

Davis, L ;

Driscoll, T ;

Frierson, L ;

Fuqua, P ;

Gardner, H ;

Golbesky, B ;

Good, B ;

Graves, J ;

Harstock, L ;

Hawkins, C ;

Hernandez, R ;

Iturriaga, E ;

Kres, J ;

Laurenzi, B ;

Lee, E ;

Leyde, D ;

Mehagian, M ;

Moses, D ;

Nash, J ;

Norwood, N ;

Parsons, J ;

Pearmain, J ;

RatliffWalker, D ;

Rightmyer, D ;

Rizzi, V ;

Smith, B ;

Soliman, M ;

Volintine, L ;

Warder, J ;

Werner, J ;

Wolf, S .

NEUROLOGY, 1996, 46 (05) :1442-1444

[5]

Osserman K, 1958, MYASTHENIA GRAVIS

[6] MYASTHENIA-GRAVIS - QUANTITATIVE-EVALUATION SYSTEM [J].

SZOBOR, A .

EUROPEAN NEUROLOGY, 1976, 14 (06) :439-446

[7] PRELIMINARY-RESULTS OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CYCLOSPORINE IN MYASTHENIA-GRAVIS [J].

TINDALL, RSA ;

ROLLINS, JA ;

PHILLIPS, JT ;

GREENLEE, RG ;

WELLS, L ;

BELENDIUK, G .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (12) :719-724

← 1 →